TGFB1 and persistent truncus arteriosus: Our data demonstrate that galunisertib attenuates the severity of TAC-induced experimental AP in rats by inducing apoptosis in acinar cells, and inhibiting the activation of TGF-β and NF-κB signal, and suppressing the secretion of pro-inflammatory cytokines.